Joseph Beck
Hematology & Oncology · Fayetteville, ARNPI 1952372120
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.9%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Stemline Therapeutics Inc. at 29.7% of the total. 2025 is the largest year on record at $8,526, 5.8 times the $1,460 reported in 2019.
Across 562 payments — averaging $38.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stemline Therapeutics Inc.$6K
- Pfizer$5K
- Novartis$3K
- AstraZeneca$1K
- Johnson & Johnson$872
- Array Biopharma Inc$636
- plus $5K from 54 others
Across 2,089 payments — averaging $16,214 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$11.1M
- AstraZeneca$6.6M
- Pfizer$5.8M
- Array Biopharma Inc$2.2M
- Merck$1.7M
- Eli Lilly$1.6M
- plus $4.9M from 23 others
What the payments were for
- Consulting fees$6,24029%
- Speaking & faculty fees$3,70017%
- Travel & lodging$1451%
- Food & beverage$9,11542%
- Education$3672%
- Other$2,19610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orserdu$6,240
How this compares
$21,763 in reported general payments places this provider in the 85th percentile of 92 hematology & oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 69 | $1,110,199 |
| RevlimidLenalidomide | 42 | $799,674 |
| BrukinsaZanubrutinib | 32 | $458,378 |
| KisqaliRibociclib Succinate | 20 | $277,572 |
| CalquenceAcalabrutinib Maleate | 14 | $217,573 |
| VerzenioAbemaciclib | 12 | $188,563 |
| ImbruvicaIbrutinib | 13 | $75,800 |
| XareltoRivaroxaban | 27 | $20,403 |
| Anastrozole | 230 | $4,086 |
| Letrozole | 226 | $3,731 |
| Imatinib Mesylate | 13 | $1,853 |
| Hydroxyurea | 67 | $1,771 |
| Prochlorperazine Maleate | 42 | $1,361 |
| Tamoxifen Citrate | 53 | $1,254 |
| Potassium Chloride | 76 | $1,129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $42 | $1,110,19969 claims |
| Bristol Myers SquibbRevlimid | $42 | $799,67442 claims |
| Beigene USA, Inc.Brukinsa | $43 | $458,37832 claims |
| NovartisKisqali | $3,455 | $277,57220 claims |
| AstraZenecaCalquence | $1,057 | $217,57314 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $102 | $188,93727 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $115 | $75,80013 claims |
| Johnson & JohnsonXarelto | $872 | $20,40327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 92 hematology & oncology providers in Arkansas.
Other hematology & oncology in Fayetteville
- Eric SchaeferFayetteville$466K
- Stephan RosenfeldFayetteville$61K
- Patrick TravisFayetteville$37K
- Gregory OakhillFayetteville$9K
- Matthew LockwoodFayetteville$8K
- K'anne ArthurFayetteville$8K
- Lynsay BrautnickFayetteville$7K
- Brooke BranderFayetteville$6K
- Mitchell RossFayetteville$3K
- Frits van RheeLittle Rock$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.